Advanced search
1 file | 198.64 KB Add to list

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

(2013) JOURNAL OF CLINICAL ONCOLOGY. 31(5). p.573-583
Author
Organization
Keywords
CD22-TARGETED IMMUNOCONJUGATE, EFFICACY, B-CELL LYMPHOMA, ANTITUMOR ANTIBIOTICS, SALVAGE THERAPY, CALICHEAMICIN, CHEMOTHERAPY, MALIGNANCIES, CMC-544, POTENT

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 198.64 KB

Citation

Please use this url to cite or link to this publication:

MLA
Fayad, Luis, Fritz Offner, Mitchell R Smith, et al. “Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-based Targeting Agents for the Treatment of non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin with Rituximab.” JOURNAL OF CLINICAL ONCOLOGY 31.5 (2013): 573–583. Print.
APA
Fayad, L., Offner, F., Smith, M. R., Verhoef, G., Johnson, P., Kaufman, J. L., Rohatiner, A., et al. (2013). Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 573–583.
Chicago author-date
Fayad, Luis, Fritz Offner, Mitchell R Smith, Gregor Verhoef, Peter Johnson, Jonathan L Kaufman, Ama Rohatiner, et al. 2013. “Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-based Targeting Agents for the Treatment of non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin with Rituximab.” Journal of Clinical Oncology 31 (5): 573–583.
Chicago author-date (all authors)
Fayad, Luis, Fritz Offner, Mitchell R Smith, Gregor Verhoef, Peter Johnson, Jonathan L Kaufman, Ama Rohatiner, Anjali Advani, James Foran, Georg Hess, Bertrand Coiffier, Myron Czuczman, Eva Gine, Simon Durrant, Michelle Kneissl, Kenneth T Luu, Steven Y Hua, Joseph Boni, Erik Vandendries, and Nam H Dang. 2013. “Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-based Targeting Agents for the Treatment of non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin with Rituximab.” Journal of Clinical Oncology 31 (5): 573–583.
Vancouver
1.
Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. JOURNAL OF CLINICAL ONCOLOGY. 2013;31(5):573–83.
IEEE
[1]
L. Fayad et al., “Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab,” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 5, pp. 573–583, 2013.
@article{4106618,
  author       = {Fayad, Luis and Offner, Fritz and Smith, Mitchell R and Verhoef, Gregor and Johnson, Peter and Kaufman, Jonathan L and Rohatiner, Ama and Advani, Anjali and Foran, James and Hess, Georg and Coiffier, Bertrand and Czuczman, Myron and Gine, Eva and Durrant, Simon and Kneissl, Michelle and Luu, Kenneth T and Hua, Steven Y and Boni, Joseph and Vandendries, Erik and Dang, Nam H},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  keywords     = {CD22-TARGETED IMMUNOCONJUGATE,EFFICACY,B-CELL LYMPHOMA,ANTITUMOR ANTIBIOTICS,SALVAGE THERAPY,CALICHEAMICIN,CHEMOTHERAPY,MALIGNANCIES,CMC-544,POTENT},
  language     = {eng},
  number       = {5},
  pages        = {573--583},
  title        = {Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab},
  url          = {http://dx.doi.org/10.1200/JCO.2012.42.7211},
  volume       = {31},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: